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SUMMARY : Twenty-nine patient with vulvar dystrophy were classified histological-
ly and were subjected to a proposed protocol of treatment by steroid hormone application 
to the local skin. Clinical response was evaluated in twenty-three of these patients. 
Observation by colposcopy and toluidine blue test were the two techniques used to direct 
biopsies. The results showed that 4 or 5 patient with lichen sclerosus and 16 of 18 patients 
with Hyperplastic and mixed dystrophy had complete symptomatic response with 
testosterone and corticosteroid respectively. Moreover 22 (96%) had more than 50% decrease 
in total lesion morphologically. It is therefore concluded that for velvar dystrophy, a 
benign epithelial disorder of the vulva steroid hormone therapy is indeed a logical and 
an effective one.
       INTRODUCTION 
 The vulvar dystrophy is an enigma and one 
of the most controversial topic as for the 
pathogenesis, clinical out-come and the malig-
nant potentiality. Recently a more satisfactory 
terminology, more emphasis on histopathology, 
conservative approaches, more prospective stud-
ies and better knowledge were attained due to 
the advancement in the techniques. And clinical 
investigative procedure have definitely con-
tributed to the better understanding of the 
vulvar dystrophic diseases. Inspite of all this 
advancement, to what extent the agony and 
morbidity of the sufferers has decreased is still 
an issue of persuance. 
 There has been very few systematic studies 
in Japan concerning vulvar dystrophy. In this 
institute a study was undertaken to evaluate the 
clinical outcome of vulvar dystrophies, where 
the patients were subjected to a proposed 
protocol of treatment (Fig. 1).
   MATERIALS AND METHODS 
 The patients referred to the Gynecology 
Department of Nagasaki University Hospital 
with vulvar complaints with the subjective 
symptom of `itching' had undergone biopsy. In 
all the cases toluidine blue test and colposcopy 
directed biopsies were obtained. In addition to 
the toluidine positive areas, multiple biosies 
were obtained from several other sites because 
of the multicentric nature of the vulvar dy-
strophic diseases. 
 Biopsy site and the size of the lesion were 
documented and photographed for references 
for the treatment assesment. Diagnosis being 
confirmed after histological examination, the 
patients were subjected to the proposed protocol 
of treatment. The steroid hormones were ap-
plied to the local skin two to three times daily 
for at least four weeks and the frequency of 
application were decreased gradually to two 
times per week, with the alleviation of the symp-
toms. The patients were examined bi-weekly
Fig. 1 Treatment protocol for vulvar dystrophy
at which time the gross appearance of vulva, 
symptomatic relief and side-effects were noted.
          RESULTS 
 The patients who had undergone biopsy of 
epithelial lesions of the vulva were 75 in total 
from January 1986 till December 1990. Among 
them vulvar dystrophy was found in 29 cases 
(37.1%). The initial histological diagnosis of 
these 29 patients are listed in Table 1. 
 The age distribution according to histological 
diagnosis in lichen sclerosus was 56.4 (SD 11.4) 
years. The age of the patients with hyperplastic 
dystrophy without atypia was 54.08 (SD 12.4) 
years and for hyperplastic dystrophy with 
atypia was 50.5 (SD 14) years. The age of the 
patients with mixed dystrophy was quite var-
iable, with majority of these patients being over 
the age of 50 years. In contrary to other fre-
quent statements the vulvar dystrophc lesions 
were obtained in some patients of reproductive 
age group too (Fig. 2). 
 Itching was the most frequent complaint 
encountered in this study. Also mass, burning 
sensation, pain and disturbance in urination 
were. the other symptoms commonly found. 
However, some of the patients were without any
symptom (Table 2). 
  The frequency of vulvar dystrophy by site is 
presented in Fig. 3. Lichen sclerosus was found 
in the labia majora and minora and also rel-
atively frequent in the prepuce of the clitoris 
and posterior labial commissure. The occur-
ence was almost symmetrical in 4/5 (80%) of the 
cases. Hyperplastic dystrophy without atypia 
-was frequent in labia majora, minora and was 
liable to spread to the prepuce of the clitoris 
and posterior labial commissure. In case of 
hyperplastic dystrophy with atypia was mostly 
localized, in the vestibule and frequently ob-
served in the labia majora and minora. 
  The treatment advocated, after histological 
diagnosis paralleling the protocal, application 
of corticosteroid (Fluocinolone acetonide 0.25-
mg/g in 10g) ointment in hyperplastic dystrophy 
without atypia and resulted in alleviation of itch. 
The symptomatic relief was prompt in this 
group, followed by demonstrable gross change 
of the vulva, which was evident by reduction 
of the size of the lesion. The final result was 
histological changes towards regression. In 
patients with hyperplastic dystrophy with 
atypia, corticosteroid completely removed the 
disease without any recurrences in 6/9 (66.7%) 
patients. In two other patients it was ac-
Table 1. Epithelial Lesions of The Vulva [Nagasaki University (Jan 1986-May 1990)] 
                       Epithelial Lesions Cases (%) 
                 Lichen sclerous 5 ( 6.4)
                 Hyperplastic, without atypia 9(11.5) 
Dystrophy mild-mod 11 (14.1) 29(37.1)                  H
yperplastic, with atypic severe I ( 1.3) 
               Mixed 3 ( 3.8)
Other benign Condyloma acuminatum 1 ( 1.3) 
l Hydradenoma 1 ( 1.3) 32(43.6)  esions V
ulvitis and others 32 (41.0) 
 In situ cancerous Carcinoma in situ 1 ( 1.3) 3 ( 3
.9)  l
esion Paget's disease 2 ( 2.6) 
                 Microinvasive carcinoma 1 ( 1.3)
 Invasive Squamous cell carcinoma 9(11.5) 12 (15.4)  carcinoma I
nvasive Paget's disease 1 ( 1.3) 
                Adenocarcinoma (Skene gland) 1 ( 1.3)
                           Table 2. Symptoms of Vulvar Dystrophy 
                   symptoms 
 lesion itching burning mass pain urinary no                                                                         disturb nce symtoms
Lichen sclerosus (5 case) 80 % 40% - 20 % 20 % -
Hyperplastic, (9 case) without atypia 77.8% - 11.1% 11.1% - 11.1% 
Hyperplastic, (12 case) with atypia 58.3% - 16.7% 8.3% - 16.7% 
Mixed (3 case) 66.7% - 33.3% - 33.3% 33.3%
Fig. 2. Age distribution in patients with vulvar dystrophies
complished by local excision of the diseased 
area. In these two patients the lesion was small, 
localized and well demarcated, which could eas-
ily be approached for excision.
 The treatment for lichen sclerosus with 2% 
testosterone propionate in a vaseline base ap-
plied locally has had dramatic response, noted 
by the symptomatic relief of itching. Subjective
Fig. 3. Frequency of vulvar dystrophies by site (%)
                          Table 3. Clinical Response to Treatment 
                                            subjective objective 
                                    cases (symptomatic relief) (decrease of lesion)
                                      complete partial 100% 50%% 50%> 
Lichen sclerosus 5 4 1 2 2 1 
Hyperplastic, without atypia 8 7 1 4 4 -
                        mild 3 3 - 3 - -
Hyperplastic, with atypia moderate 5 4 1 3 2 -
                        severe 1 1 1 -
Mixed 1 1 1 -
Total 23 20 3 12 10 1 
                                       (87.0%) (13.0%) (52.2%) (43.5%) (4.3%)
symptoms disappeared or decreased in 4/5 (80%) 
of the cases. The improvement in the external 
morphology was more vivid in these patients. 
The treatment offered for mixed dystrophy 
without atypia was corticosteroid and testoster-
one ointment application was of great benifit. 
The clinical response after treatment in 23 of 
the vulvar dystrophic patient are represented 
in Table 3.
         DISCUSSION 
 In the previous times the treatment of choice 
for vulvar dystrophy was surgery by mutilat-
ing vulvectomy. Most clinicians at that time 
believed that this method relieves symptoms 
and provides an adequate prophylaxis against 
the inevitable development of carcinoma. In the 
recent times there are several reports investi-
gating the relationship of vulvar dystrophy to
the development of carcinoma'' 2. 3. "And these 
reports revealed that the risk of carcinoma of 
the vulva developing in a woman with vulvar 
dystrophy is approximately 2-5% at presentation 
with additional risk of developing malignancy 
from vulvar dystrophy is extremely small. 
 Previously, several kinds of topical agents has 
been tried for vulvar dystrophy. Vitamin A5' 
and Mercuric Sulphide' were used in the early 
times, but they did not result in the resolution 
of the disease, either morphologically or micro-
scopically. Jasionowski) has tried a topical 
application of progesterone, which resulted in 
a good response but the treatment was advo-
cated in a small group of patients only. As a 
medical approach, intradermal injection of 
triamnicilone' and absolute alcohol" have been 
used. The result of these agents were not sat-
isfactory. 
 August") employed cryosurgery on 12 patients 
and reported satisfactory results, without fur-
ther treatment after three years in only 25% of 
the cases. 
 Surgical therapy for vulvar dystrophies has 
been disappointing because most patients ex-
perienced recurrences'. Rettenmaier" report-
ed on skinning vulvectomy in vulvar dystrophic 
patients and observed recurrences in 50% of the 
patients at 45-96 months after initial surgery. 
Di Paola121 treated vulvar dystrophy by grafting 
technique after vulvectomy. Two years later, 
the grafted skin has developed recurrence. 
 Recently, laser therapy has been used for the 
treatment of this disease"). But a high recur-
rence rate has been found after this treatment. 
Some authorities suggest that persisting lesion 
after laser therapy may respond more favorably 
to topical steroid, but this mode of treatment 
has been evaluated in only small number of 
patients. The therapeutic value of laser therapy 
in vulvar dystrophies is yet to be proved. 
 Effective treatment of vast majority of pa-
tients can be achieved medically by steroid 
hormone. The local application of corticoster-
oid has been proved to be of great benifit in 
most patients becoming free of symptoms. In 
a prospective study by Kaufman8' 24 out of 39 
hyperplastic dystrophy without atypia had com-
plete relief of symptoms with both morpho-
logical and histological changes to regression.
Friedrich" similarly reported on prompt relief 
of symptoms in hyperplastic dystrophic patients 
by the treatment using topical application of a 
cream containing crotamine diluted with a 
hydrocortisone compound. 
 Cinberg''" was the first who noted the ef-
ficiency of topical testosterone in lichen sclero-
sus. His treatment was employed in a large 
series by several authorities""". Recently 
Friedrich" in a report summarized the results 
of testosterone ointment for the treatment of 
lichen sclerosus and mixed dystrophy. In ad-
dition to his own results, he reported on the 
results of several authorities. Of 184 patients 
treated, 172 (93%) had shown improvement after 
testosterone therapy, both macroscopically and 
microscopically. 
 Vulvar dystrophy is a common gynecological 
problem causing sufferings and morbidity in 
large number of women. It is to be emphasiz-
ed that biopsy is mandatory before advocat-
ing treatment in order to exclude malignancy 
during the first visit and that re-biopsy is also 
essential for the confirmation of regression of 
the disease. The present report has demon-
strated the dramatic effects of steroid hormone 
therapy on vulvar dystrophy, irrespective of 
dysplasia. In the study, 4 of the 5 patients of 
lichen sclerosus and 16 of the 18 patients of 
hyperplastic and mixed dystrophy had com-
plete symptomatic response to testosterone and 
corticosteroid respectively. Moreover, morpho-
logically 22/23 (96%) of the patients had more 
than 50% decrease in total lesion. These data 
indicate that the protocol of treatment describ-
ed here can eliminate the agonising symptoms 
without a need for mutilating surgery. It is 
likely that the sufferings and morbidity in 
vulvar dystrophic patients could be controlled 
by this treatment.
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